The announcement of projected R&D and SG&A expenses for FY24 by Coherus BioSciences provides insight into the company's financial planning and operational focus. While this information is crucial for understanding the company's future investment in growth and operational efficiency, the direct short-term impact on the stock price is uncertain. Investors may interpret this as a sign of strategic investment in growth or as a potential pressure on profit margins, depending on the context of the company's overall financial health and market conditions.